CHF Exacerbation: A Comprehensive Guide to Differential Diagnosis and Management

Congestive Heart Failure (CHF) is a pervasive global health issue, characterized by the heart’s inability to pump blood effectively to meet the body’s needs. This condition, often stemming from underlying structural or functional cardiac impairments, leads to a cascade of symptoms including fatigue, dyspnea, reduced exercise tolerance, and systemic congestion. While the general management of CHF focuses on symptom relief and hemodynamic stabilization, accurately diagnosing the cause of a CHF exacerbation is crucial for effective treatment and improved patient outcomes. This article delves into the differential diagnosis of CHF exacerbations, aiming to provide a comprehensive understanding for healthcare professionals.

Understanding Congestive Heart Failure and Its Exacerbations

Congestive Heart Failure, as defined by the American College of Cardiology (ACC) and the American Heart Association (AHA), is a complex syndrome resulting from any structural or functional impairment of the heart’s ventricles. Ischemic heart disease remains the leading global cause of CHF and mortality. The global prevalence of CHF is estimated at around 26 million individuals, imposing significant healthcare burdens and diminishing patient quality of life. Effective diagnosis and management are paramount to reduce hospital readmissions, morbidity, and mortality, ultimately enhancing patient well-being.¹

Heart failure etiology is diverse and extensive. Management strategies are broadly aimed at alleviating pulmonary and systemic congestion and stabilizing hemodynamics, irrespective of the underlying cause. Treatment necessitates a multifaceted approach, encompassing patient education, optimized medication regimens, and strategies to minimize acute exacerbations.

Left ventricular ejection fraction (LVEF) is a key parameter in classifying heart failure.¹

• Heart Failure with Reduced Ejection Fraction (HFrEF): LVEF ≤ 40%
• Heart Failure with Mildly Reduced Ejection Fraction (HFmrEF): LVEF 41% – 49% with evidence of HF (elevated cardiac biomarkers or filling pressures)
• Heart Failure with Preserved Ejection Fraction (HFpEF): LVEF ≥ 50% with evidence of HF (elevated cardiac biomarkers or filling pressures)
• Heart Failure with Improved Ejection Fraction (HFimpEF): LVEF > 40%, with a previous LVEF ≤ 40%

HFpEF, often underdiagnosed, accounts for a significant proportion of CHF cases, ranging from 44% to 72%. Echocardiography in HFpEF typically reveals LVEF ≥ 50% alongside evidence of impaired diastolic function. Hypertension is the most prominent risk factor, with others including advanced age, female gender, and diabetes.²

The ACC and AHA classify HF into stages, with Stages A and B being pre-clinical and Stages C and D denoting symptomatic heart failure.

ACC/AHA Heart Failure Stages

• Stage A: At Risk for HF. Risk factors present but no symptoms, structural heart disease, or elevated biomarkers. Risk factors include hypertension, diabetes, metabolic syndrome, cardiotoxic medications, or genetic predisposition to cardiomyopathy.
• Stage B: Pre-Heart Failure. Structural heart disease or elevated filling pressures/biomarkers without signs or symptoms of HF.
• Stage C: Symptomatic Heart Failure. Structural heart disease with current or past HF symptoms.
• Stage D: Advanced Heart Failure. Refractory symptoms interfering with daily life or recurrent hospitalizations despite optimal guideline-directed medical therapy.

The New York Heart Association (NYHA) Functional Classification, a subjective assessment by clinicians, categorizes patients based on symptom severity and guides therapy in symptomatic HF.

New York Heart Association Functional Classification³

• Class I: Symptoms only with greater than ordinary physical activity.
• Class II: Symptoms with ordinary physical activity.
• Class III: Symptoms with minimal physical activity.
  • Class IIIa: No dyspnea at rest.
  • Class IIIb: Recent onset of dyspnea at rest.
• Class IV: Symptoms at rest.

Etiology of Congestive Heart Failure and Exacerbations

Identifying the underlying cause of CHF is crucial for targeted treatment strategies. Coronary artery disease (CAD) leading to ischemic heart disease is the most prevalent cause. Etiologies are broadly categorized into intrinsic heart diseases and pathologies that are infiltrative, congenital, valvular, myocarditis-related, high-output failure, and secondary to systemic diseases.², ⁴ These categories often overlap. The four most common causes, accounting for approximately two-thirds of CHF cases, are ischemic heart disease, chronic obstructive pulmonary disease (COPD), hypertensive heart disease, and rheumatic heart disease. Higher-income countries predominantly see ischemic heart disease and COPD, whereas lower-income countries have higher rates of hypertensive heart disease, cardiomyopathy, rheumatic heart disease, and myocarditis.

Common Etiologies of CHF:

• Ischemic Heart Disease: The leading global cause, resulting from reduced blood flow to the heart muscle and decreased ejection fraction. Its incidence is rising in developing nations with lifestyle and dietary shifts and improved management of infectious diseases.
• Valvular Heart Disease: A significant intrinsic cardiac condition. Rheumatic heart disease is the most common cause in younger populations, primarily affecting the mitral and aortic valves.⁵ Age-related degeneration is the most common overall cause of valvular disease, with the aortic valve being most frequently affected.
• Hypertension: A major contributor to CHF, even without CAD. Elevated blood pressure increases afterload and induces neurohormonal changes, leading to ventricular hypertrophy.² Aggressive hypertension management is proven to reduce CHF incidence.
• Cardiomyopathy: A diverse group of diseases characterized by ventricular enlargement and dysfunction, not secondary to ischemic, valvular, hypertensive, or congenital heart disease. Types include hypertrophic, dilated, restrictive, arrhythmogenic right ventricular, and left ventricular noncompaction.⁶ Genetic factors play a significant role in many cardiomyopathies.
• Inflammatory Cardiomyopathy (Myocarditis): Often caused by viral infections, but also bacterial, fungal, protozoal, toxic, drug-induced, or immune-mediated. Chagas disease, caused by Trypanosoma cruzi, is a major cause in Latin America. Viral causes include adenoviruses, enteroviruses, herpes viruses, and coronaviruses (including COVID-19).⁷
• Infiltrative Cardiomyopathies: Lead to restrictive cardiomyopathy, characterized by diastolic dysfunction and restrictive filling dynamics despite normal systolic function.⁶, ⁸ Cardiac amyloidosis, caused by misfolded protein deposits, is a notable example. Sarcoidosis and cardiac hemochromatosis are other infiltrative causes.
• Takotsubo Cardiomyopathy (Stress-Induced Cardiomyopathy): Causes transient left ventricular wall motion abnormalities, often triggered by stress. Mechanisms include coronary vasospasm, microcirculatory dysfunction, and sympathetic nervous system activation.¹¹, ¹², ¹³
• Peripartum Cardiomyopathy: Occurs during late pregnancy or postpartum, associated with LV systolic dysfunction. Genetic predisposition and factors like advanced maternal age and multifetal pregnancies are risk factors.¹⁴
• Obesity: A significant risk factor for CHF, particularly in younger individuals. Adipose tissue cytokines and natriuretic peptide degradation are implicated.¹⁵, ¹⁶, ¹⁷
• Tachycardia and Arrhythmia: Can induce a low-output CHF state. Rate control can often reverse these changes due to myocardial hibernation.¹⁸
• Thyrotoxicosis: A rare cause of HF despite a hyperdynamic state, potentially due to RAAS activation and increased blood volume. Sustained tachycardia can also contribute.¹⁹
• High-Output Cardiac Failure: Associated with conditions like thiamine deficiency, liver disease, and arteriovenous shunts. Characterized by decreased afterload and increased metabolic demand.²⁰, ²¹, ²², ²³

Epidemiology of Congestive Heart Failure

Accurate global CHF epidemiology is challenging due to variations in diagnostic methods, geographical distribution, and adherence to uniform classification. In 2017, approximately 1.2 million hospitalizations were attributed to CHF, with a rising proportion of HFpEF cases.¹

While incidence rates may have plateaued, prevalence is increasing due to improved therapies, although this hasn’t consistently translated to better quality of life or fewer hospitalizations. Global prevalence is estimated at 64.34 million cases, resulting in substantial disability-adjusted life years (YLDs) and healthcare expenditures.²⁴

Age is a major risk factor. CHF prevalence increases significantly with age across all classifications. The Framingham Heart Study demonstrated a steep increase in prevalence with age, highlighting the age-related risk.²⁵ Incidence doubles every decade after 65 in men and triples in women. Men generally have higher rates of heart disease and CHF globally.²⁶, ²

Race also plays a role, with Black patients exhibiting a 25% higher CHF prevalence than White patients in global registries. CHF remains a leading cause of hospitalization in older adults and a significant contributor to cardiovascular deaths in the US.²⁶

International epidemiological data mirrors these trends, showing increasing incidence with age, metabolic risk factors, and sedentary lifestyles. Ischemic cardiomyopathy and hypertension are significant contributors to CHF in developing countries.²⁷ Some smaller studies suggest a higher prevalence of isolated right heart failure in these regions, potentially linked to higher rates of tuberculous, pericardial, and lung diseases, though robust data is lacking.

Pathophysiology of Congestive Heart Failure

CHF is a progressive condition. Initial cardiac insults, whether acute or chronic, trigger compensatory mechanisms aimed at maintaining cardiac output. These mechanisms, when exhausted, lead to maladaptation.

Early CHF stages involve compensatory mechanisms to maintain cardiac output. Chronic sympathetic nervous system activation leads to reduced beta-receptor responsiveness and adrenaline stores, resulting in myocardial hypertrophy and hypercontractility.²⁸ Increased sympathetic drive also activates the renin-angiotensin-aldosterone system (RAAS), causing vasoconstriction and sodium retention.²⁸, ²⁹

Reduced cardiac output and increased sympathetic drive stimulate RAAS, further increasing salt and water retention and vasoconstriction, perpetuating maladaptive cardiac changes and progressive HF. Angiotensin II release from RAAS promotes myocardial hypertrophy and interstitial fibrosis, contributing to remodeling.³

Decreased cardiac output also stimulates neuroendocrine release of epinephrine, norepinephrine, endothelin-1 (ET-1), and vasopressin, causing vasoconstriction and increased afterload. Increased cyclic adenosine monophosphate (cAMP) elevates cytosolic calcium in myocytes, increasing contractility but impairing relaxation. This increased afterload and contractility with impaired relaxation increases myocardial oxygen demand, paradoxically leading to myocardial cell death and apoptosis. This cycle of cell death, decreased EF, increased LV volume and pressure, and pulmonary congestion continues.²⁹, ³⁰

Renal hypoperfusion triggers antidiuretic hormone (ADH) release, further exacerbating sodium and water retention. Increased venous and intraabdominal pressure reduces renal blood flow, decreasing glomerular filtration rate (GFR).³¹

Decompensated CHF is characterized by peripheral vasoconstriction and increased preload to the failing heart. Natriuretic peptides BNP and ANP are released but are ineffective in counteracting sodium and water retention.³¹

Neprilysin, an enzyme that degrades BNP, ANP, and bradykinin, is a therapeutic target. Sacubitril/valsartan combines a neprilysin inhibitor with an angiotensin receptor blocker to enhance natriuretic peptide effects while blocking RAAS.³², ³³

HFrEF and HFpEF, while both leading to CHF, involve different pathophysiological mechanisms and require tailored treatments. HFpEF is characterized by impaired myocardial relaxation and increased ventricular stiffness due to increased afterload, leading to similar maladaptive hemodynamics and progressive HF. HFpEF patients are often older, female, and hypertensive, with higher rates of atrial fibrillation and anemia, potentially facing a worse prognosis than HFrEF.³⁴, ³⁵

History and Physical Examination in CHF Exacerbation

History Taking:

Diagnosis and classification of CHF rely heavily on symptom presentation and physical examination. A detailed history of symptoms, comorbidities, and functional capacity is crucial for effective management.

Acute CHF exacerbations primarily manifest with congestion signs and may include organ hypoperfusion or cardiogenic shock.³⁶ Shortness of breath is the most common symptom, requiring further characterization as exertional, positional (orthopnea), acute, or chronic. Other common symptoms include chest pain, anorexia (due to hepatic congestion and bowel edema), exertional fatigue, and recumbent cough (orthopnea). Abdominal discomfort can arise from hepatic congestion or ascites. Arrhythmias may present as palpitations, presyncope, or syncope.

Edema, particularly in the lower extremities, is a significant morbidity factor, limiting mobility and balance. Fluid retention can lead to substantial weight gain (> 20 lbs).

While acute HF presents with overt respiratory distress, orthopnea, and paroxysmal nocturnal dyspnea, chronic HF patients may limit activity, masking symptoms. Identifying triggers for acute decompensation, such as recent infections, medication non-adherence, NSAID use, or increased salt intake, is essential.

Physical Examination:

Examination findings vary with disease stage and acuity. Patients may exhibit left-sided, right-sided, or combined HF symptoms.

General Examination: Patients with severe or acutely decompensated CHF may present with anxiety, diaphoresis, tachycardia, and tachypnea. Chronic decompensated HF can lead to cachexia. Chest examination may reveal pulmonary rales, a classic sign of moderate-to-severe HF. Wheezing can occur in acute decompensated HF. Severe pulmonary congestion may produce frothy, blood-tinged sputum. However, absence of rales doesn’t rule out congestion. Jugular venous distention (JVD) and hepatojugular reflux (HJR) are key findings in elevated filling pressures.

Stage D HF may show poor perfusion signs like hypotension, reduced capillary refill, cold extremities, altered mental status, and decreased urine output. Pulsus alternans, an alternating pulse strength, suggests severe ventricular dysfunction. Irregular pulse may indicate atrial fibrillation or ectopic beats. Peripheral edema is common in HF.³⁷ Daily weight monitoring is crucial for assessing fluid retention.

Precordial Examination: Findings include S3 gallop (early HF sign), displaced apex beat (dilated heart), and murmurs of associated valvular lesions (mitral regurgitation, aortic stenosis/regurgitation, tricuspid regurgitation). Pulmonary hypertension may manifest as palpable or loud P2 or parasternal heave. Congenital heart disease may present with clubbing, cyanosis, and second heart sound splitting.

S3 gallop is a significant early HF finding.³⁸ Hypertensive heart disease may present with S4 or loud A2. HFpEF may show S4 due to ventricular noncompliance.

The Framingham Diagnostic Criteria for Heart Failure, requiring 2 major or 1 major and 2 minor criteria, is highly sensitive but less specific.

Framingham Diagnostic Criteria for Heart Failure³⁷

Major Criteria:

• Acute pulmonary edema
• Cardiomegaly
• Hepatojugular reflux
• Neck vein distention
• Paroxysmal nocturnal dyspnea or orthopnea
• Pulmonary rales
• Third heart sound (S3 Gallop)

Minor Criteria:

• Ankle edema
• Dyspnea on exertion
• Hepatomegaly
• Nocturnal cough
• Pleural effusion
• Tachycardia (heart rate > 120 bpm)

Diagnostic Evaluation of CHF Exacerbation

Comprehensive evaluation is essential for patients presenting with CHF exacerbation. This includes initial blood work and further investigations based on clinical presentation and suspected etiology.¹

Initial Blood Tests:

• Complete Blood Count (CBC): May reveal anemia or leukocytosis (infection trigger).
• Complete Renal Profile: Assesses renal function, guiding medication choices (RAAS inhibitors, SGLT-2 inhibitors, diuretics). Baseline renal function is crucial. Serum sodium levels are prognostic, with hyponatremia associated with increased mortality in CHF.³⁹
• Liver Profile: Detects hepatic congestion due to HF, which can elevate gamma-glutamyl transferase, aspartate aminotransferase (AST), and alanine aminotransferase (ALT).⁴⁰

Further Investigations:

• Urine Studies: Urine and serum electrophoresis and monoclonal light chain assays if amyloidosis is suspected. Bone scintigraphy may be considered if suspicion remains high despite negative light chain tests.¹
• Serum B-type Natriuretic Peptide (BNP) or N-terminal pro-BNP (NT-ProBNP): Helps differentiate cardiac from non-cardiac dyspnea. BNP is an independent predictor of elevated LV end-diastolic pressure and mortality risk. NT-ProBNP has a longer half-life. Natriuretic peptides should not solely drive treatment in clear CHF cases and can be elevated in renal dysfunction, atrial fibrillation, and older patients, and falsely low in obesity, hypothyroidism, and advanced HF. ⁴¹
• Troponin-I or T: Elevated levels suggest ongoing myocardial injury and predict adverse outcomes.
• Electrocardiogram (ECG): May show prior infarction, chamber enlargement, conduction delays, arrhythmia, or clues to specific etiologies. Low voltage ECG can suggest amyloidosis; epsilon waves ARVC. QRS duration > 120ms predicts response to device therapy.
• Chest Radiograph: Assesses pulmonary congestion and cardiomegaly. Findings include enlarged cardiac silhouette, pulmonary edema, vascular congestion, and Kerley B lines in severe HF. Absence doesn’t rule out CHF.³⁷

• Echocardiography: Initial imaging modality, readily available, quantifies ventricular function, structural abnormalities, and wall motion abnormalities. Transesophageal echocardiography (TEE) may be needed in obese, pregnant, or ventilated patients. Rate control is needed for tachyarrhythmias.³⁷
• Cardiac Catheterization: Diagnoses ischemic cardiomyopathy and evaluates intracardiac pressures.
• Computed Tomography (CT): Assesses coronary artery disease (especially in younger patients), congenital heart disease, cardiac tumors, stent patency, and grafts.
• SPECT-Myocardial Perfusion Imaging: Detects ischemia in new-onset LV dysfunction without angiography. Useful for CAD assessment in patients without prior ischemia but elevated troponin. ECG-gated imaging evaluates EF and wall motion.⁴²
• Cardiac Magnetic Resonance Imaging (MRI): Essential when clinical findings and echocardiography are discordant. Precisely evaluates volumes, chamber sizes, ventricular function, valvular disease, congenital heart disease, myocarditis, dilated/infiltrative cardiomyopathy, and ARVC.⁴³
• Radionuclide Multiple-Gated Acquisition (MUGA) Scan: Reliable EF measurement when other studies are discordant.⁴²
• Noninvasive Stress Imaging: Stress echocardiography, MRI, and SPECT for assessing revascularization benefit in ischemic cardiomyopathy.
• Genetic Testing: Identifies genetic variants in cardiomyopathies (Titin, laminin, myosin, troponin mutations).⁴⁴

Differential Diagnosis of CHF Exacerbation

When a patient presents with symptoms suggestive of a CHF exacerbation, it is crucial to consider other conditions that can mimic or contribute to these symptoms. A thorough differential diagnosis is essential to ensure appropriate management and avoid misdiagnosis. The differential diagnosis for CHF exacerbation includes conditions presenting with similar symptoms such as dyspnea, edema, and fatigue.

Pulmonary Causes of Dyspnea:

• Acute Respiratory Distress Syndrome (ARDS): Characterized by acute onset of hypoxemia and bilateral pulmonary infiltrates, often in the setting of sepsis, pneumonia, or trauma. Differentiating ARDS from cardiogenic pulmonary edema can be challenging but key features of ARDS include a history of risk factors, severe hypoxemia unresponsive to oxygen therapy, and often, absence of cardiomegaly on chest X-ray.
• Pulmonary Embolism (PE): Sudden onset dyspnea, chest pain, and hypoxemia should raise suspicion for PE. Risk factors for venous thromboembolism, such as recent surgery, immobilization, malignancy, and hypercoagulable states, should be assessed. While PE can cause right heart strain and elevated BNP, echocardiography and CT angiography are essential for diagnosis.
• Pneumonia: Infection of the lung parenchyma can present with cough, fever, and dyspnea. While pneumonia can exacerbate underlying CHF, it can also mimic a CHF exacerbation, particularly in elderly patients. Focal lung findings on auscultation and consolidation on chest X-ray are more suggestive of pneumonia.
• Chronic Obstructive Pulmonary Disease (COPD) Exacerbation: Patients with COPD may present with increased dyspnea, wheezing, and cough. History of smoking and chronic respiratory symptoms are important. While COPD can coexist with CHF, an acute exacerbation of COPD needs to be distinguished, often based on history, physical exam (hyperinflation, decreased breath sounds), and pulmonary function tests when available.
• Asthma Exacerbation: Acute worsening of asthma can cause dyspnea, wheezing, and cough. History of asthma and triggers like allergens or respiratory infections are important. Bronchodilator responsiveness is a key feature distinguishing asthma.

Renal Causes of Volume Overload:

• Acute Kidney Injury (AKI) and Chronic Kidney Disease (CKD): Both AKI and CKD can lead to fluid retention and volume overload, mimicking CHF exacerbation. Elevated creatinine and BUN levels, abnormal electrolytes, and urine analysis are crucial diagnostic clues. While renal dysfunction is common in CHF (cardiorenal syndrome), primary renal pathology needs to be considered.
• Nephrotic Syndrome: Proteinuria, hypoalbuminemia, edema, and hyperlipidemia characterize nephrotic syndrome. Severe edema, including periorbital and generalized edema, can resemble CHF. Urine protein quantification is essential for diagnosis.

Hepatic Causes of Edema:

• Cirrhosis: Liver cirrhosis can cause ascites, peripheral edema, and dyspnea due to hepatopulmonary syndrome or pleural effusions. Stigmata of chronic liver disease (jaundice, spider angiomata, palmar erythema), abnormal liver function tests, and imaging studies are important for diagnosis.

Other Conditions:

• Anemia: Severe anemia can cause high-output heart failure and dyspnea. CBC will reveal low hemoglobin and hematocrit.
• Sepsis: Systemic infection can lead to distributive shock and mimic some features of CHF exacerbation, including tachycardia and tachypnea. Fever, leukocytosis, and identification of an infectious source are crucial.
• Superior Vena Cava (SVC) Syndrome: Obstruction of the SVC can cause facial and upper extremity edema, dyspnea, and cough, potentially mimicking right-sided heart failure. History of malignancy or indwelling catheters should raise suspicion.

Key Differentiators:

• History and Risk Factors: Detailed history of cardiac disease, pulmonary disease, renal disease, liver disease, and other comorbidities is vital. Risk factors for PE, ARDS, and sepsis should be assessed.
• Physical Examination: While findings like rales and edema are common in CHF, specific findings may point towards other diagnoses (e.g., focal lung findings in pneumonia, wheezing in COPD/asthma, jaundice in cirrhosis).
• Laboratory and Imaging Studies: BNP/NT-proBNP levels are helpful but not specific. CBC, renal and liver function tests, urine studies, chest X-ray, ECG, echocardiography, CT angiography, and pulmonary function tests are essential to differentiate CHF exacerbation from other conditions.

In summary, a comprehensive approach involving detailed history, thorough physical examination, and judicious use of laboratory and imaging studies is crucial for accurate differential diagnosis of CHF exacerbations. Recognizing and differentiating these mimicking conditions is paramount for guiding appropriate and timely management.

Treatment and Management of CHF Exacerbation

The primary goals in managing CHF exacerbations are to alleviate symptoms, stabilize hemodynamics, identify and address precipitating factors, and optimize long-term management strategies to prevent future exacerbations. Treatment approaches are tailored to the patient’s clinical presentation, hemodynamic status, and underlying etiology.

General Management Principles:

• Oxygen Therapy: Supplemental oxygen is indicated for hypoxemia. Non-invasive ventilation (NIV) or mechanical ventilation may be necessary in severe respiratory distress.
• Diuretics: Loop diuretics (furosemide, bumetanide, torsemide) are the cornerstone of therapy to reduce volume overload and congestion. Dosage and route of administration (IV vs. oral) depend on the severity of congestion and renal function. Thiazide diuretics (metolazone) can be added for diuretic resistance.
• Vasodilators: Nitrates (nitroglycerin, isosorbide dinitrate) reduce preload and afterload, improving symptoms, particularly in hypertensive CHF exacerbations. Nesiritide (recombinant BNP) can be used for vasodilation and diuresis in acute decompensated HF, though its role is less emphasized in current guidelines.
• Inotropes: Dobutamine and milrinone are inotropic agents used in patients with severe low cardiac output and cardiogenic shock. These are typically reserved for short-term use in hospitalized patients due to potential pro-arrhythmic effects and increased mortality with prolonged use.
• Afterload Reduction: For patients with HFrEF, optimizing guideline-directed medical therapy (GDMT) is crucial. This includes ACE inhibitors or ARBs (or ARNI), beta-blockers, MRAs, and SGLT2 inhibitors. Up-titration of these medications should be considered during and after hospitalization for exacerbation, as tolerated.
• Fluid and Sodium Restriction: Moderate sodium restriction (2-3 grams per day) and fluid restriction (1.5-2 liters per day) may be recommended, particularly in patients with persistent volume overload or hyponatremia.
• Management of Underlying Conditions: Addressing precipitating factors is crucial. This includes treating infections, managing arrhythmias, addressing myocardial ischemia, and correcting medication non-adherence.

Stage-Specific Management (Adapted from ACC/AHA Guidelines):

• Stage A (At-Risk): Focus on risk factor modification: hypertension control with GDMT, SGLT2 inhibitors for type 2 diabetes, lifestyle changes (healthy diet, exercise, weight management, smoking cessation).
• Stage B (Pre-HF): Prevent clinical HF and reduce mortality: ACE inhibitors for LVEF ≤ 40%, statins and beta-blockers for LVEF ≤ 40% with prior ACS/MI, primary prevention ICD for LVEF ≤ 30% and NYHA Class I, beta-blockers for LVEF ≤ 40%, avoid thiazolidinediones and non-dihydropyridine calcium channel blockers in LVEF ≤ 50%.
• Stage C (HF): Multidisciplinary management, patient education, respiratory vaccinations, screening for frailty/depression/social support, low-sodium diet, exercise training, diuretics for congestion, ARNI (or ACEi/ARB), beta-blockers (carvedilol, bisoprolol, metoprolol succinate), MRA (if eGFR > 30 and K+ < 5.0), SGLT2 inhibitors, hydralazine/nitrate for African Americans with NYHA Class III-IV HFrEF, ivabradine (if HR > 70 bpm), digoxin (limited role), vericiguat (in recent HF), device therapy (ICD, CRT), revascularization (if CAD), valvular interventions.
• Stage D (Advanced HF): HF specialist referral, inotropic support/device therapy (bridge to transplant), mechanical cardiac support (LVAD/ECMO), cardiac transplant (selected patients), palliative care, shared decision-making on goals of care.

Prognosis and Complications of CHF

CHF prognosis remains serious, despite advances in therapy. Mortality rates post-hospitalization are significant: approximately 10% at 30 days, 22% at 1 year, and 42% at 5 years, exceeding 50% in Stage D HF.⁴⁸

The Ottawa Heart Failure Risk Score is a useful tool for predicting short-term mortality and readmission risk in emergency department CHF presentations.⁴⁹

Ottawa Heart Failure Risk Score:

One point each:

• History of stroke/TIA
• Oxygen saturation < 90%
• Heart rate > 110 bpm (3-minute walk test)
• Acute ischemic ECG changes
• NT-ProBNP > 5000 ng/L

Two points each:

• Prior mechanical ventilation for respiratory distress
• Heart rate > 110 bpm (presentation)
• BUN > 33.6 mg/dL
• Bicarbonate > 35 mg/dL

CHF Complications:

• Reduced quality of life
• Arrhythmia and sudden cardiac death
• Cardiac cachexia
• Cardiorenal disease
• Liver dysfunction
• Functional valvular insufficiencies
• Thromboembolism risk
• Recurrent hospitalizations and nosocomial infections

Consultations and Patient Education

Consultations depend on CHF stage and management strategy, often including HF specialists, cardiac transplant teams (Stage D), cardiac imaging radiologists, cardiac rehabilitation, dieticians, and palliative care.

Patient education is crucial for risk factor reduction, medication adherence, symptom self-monitoring, trigger avoidance, and overall self-care. Close follow-up, home-based visits, telephone support, and remote monitoring enhance patient management. Socioeconomic support is also vital.

Enhancing Healthcare Team Outcomes

CHF management requires a multidisciplinary approach involving nurses, pharmacists, social workers, case managers, primary care providers, and cardiologists. Specialty-trained HF nurses educate patients on lifestyle modifications and medication adherence. Clinical pharmacists optimize medication regimens and minimize drug interactions. Social workers and case managers provide community and home support. Collaborative interprofessional care is essential to improve quality of life and decrease mortality in CHF patients.

Review Questions

(Original article’s review questions are omitted as per instructions)

References

(References are kept as in the original article)

¹Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW., ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 May 03;145(18):e895-e1032. [PubMed: 35363499]

²Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol. 2016 Jun;13(6):368-78. [PMC free article: PMC4868779] [PubMed: 26935038]

³CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987 Jun 04;316(23):1429-35. [PubMed: 2883575]

⁴Lind L, Ingelsson M, Sundstrom J, Ärnlöv J. Impact of risk factors for major cardiovascular diseases: a comparison of life-time observational and Mendelian randomisation findings. Open Heart. 2021 Sep;8(2) [PMC free article: PMC8438838] [PubMed: 34518286]

⁵Noubiap JJ, Agbor VN, Bigna JJ, Kaze AD, Nyaga UF, Mayosi BM. Prevalence and progression of rheumatic heart disease: a global systematic review and meta-analysis of population-based echocardiographic studies. Sci Rep. 2019 Nov 19;9(1):17022. [PMC free article: PMC6863880] [PubMed: 31745178]

⁶Kim KH, Pereira NL. Genetics of Cardiomyopathy: Clinical and Mechanistic Implications for Heart Failure. Korean Circ J. 2021 Oct;51(10):797-836. [PMC free article: PMC8484993] [PubMed: 34327881]

⁷Rezkalla SH, Kloner RA. Viral myocarditis: 1917-2020: From the Influenza A to the COVID-19 pandemics. Trends Cardiovasc Med. 2021 Apr;31(3):163-169. [PMC free article: PMC7965406] [PubMed: 33383171]

⁸Muchtar E, Blauwet LA, Gertz MA. Restrictive Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. Circ Res. 2017 Sep 15;121(7):819-837. [PubMed: 28912185]

⁹Shams P, Ahmed I. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 30, 2023. Cardiac Amyloidosis. [PubMed: 35593829]

¹⁰Brown KN, Pendela VS, Ahmed I, Diaz RR. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 30, 2023. Restrictive Cardiomyopathy. [PubMed: 30725919]

¹¹Matta AG, Carrié D. Epidemiology, Pathophysiology, Diagnosis, and Principles of Management of Takotsubo Cardiomyopathy: A Review. Med Sci Monit. 2023 Mar 06;29:e939020. [PMC free article: PMC9999670] [PubMed: 36872594]

¹²Bairashevskaia AV, Belogubova SY, Kondratiuk MR, Rudnova DS, Sologova SS, Tereshkina OI, Avakyan EI. Update of Takotsubo cardiomyopathy: Present experience and outlook for the future. Int J Cardiol Heart Vasc. 2022 Apr;39:100990. [PMC free article: PMC8913320] [PubMed: 35281752]

¹³Ahmad SA, Brito D, Khalid N, Ibrahim MA. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): May 22, 2023. Takotsubo Cardiomyopathy. [PubMed: 28613549]

¹⁴DeFilippis EM, Beale A, Martyn T, Agarwal A, Elkayam U, Lam CSP, Hsich E. Heart Failure Subtypes and Cardiomyopathies in Women. Circ Res. 2022 Feb 18;130(4):436-454. [PMC free article: PMC10361647] [PubMed: 35175847]

¹⁵Wong CM, Hawkins NM, Jhund PS, MacDonald MR, Solomon SD, Granger CB, Yusuf S, Pfeffer MA, Swedberg K, Petrie MC, McMurray JJ. Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity). J Am Coll Cardiol. 2013 Nov 12;62(20):1845-54. [PubMed: 23850914]

¹⁶Sciomer S, Moscucci F, Salvioni E, Marchese G, Bussotti M, Corrà U, Piepoli MF. Role of gender, age and BMI in prognosis of heart failure. Eur J Prev Cardiol. 2020 Dec;27(2_suppl):46-51. [PMC free article: PMC7691623] [PubMed: 33238736]

¹⁷Volpe M, Gallo G. Obesity and cardiovascular disease: An executive document on pathophysiological and clinical links promoted by the Italian Society of Cardiovascular Prevention (SIPREC). Front Cardiovasc Med. 2023;10:1136340. [PMC free article: PMC10040794] [PubMed: 36993998]

¹⁸Kim DY, Kim SH, Ryu KH. Tachycardia induced Cardiomyopathy. Korean Circ J. 2019 Sep;49(9):808-817. [PMC free article: PMC6713829] [PubMed: 31456374]

¹⁹Anakwue RC, Onwubere BJ, Anisiuba BC, Ikeh VO, Mbah A, Ike SO. Congestive heart failure in subjects with thyrotoxicosis in a black community. Vasc Health Risk Manag. 2010 Aug 09;6:473-7. [PMC free article: PMC2922308] [PubMed: 20730063]

²⁰Schoenenberger AW, Schoenenberger-Berzins R, der Maur CA, Suter PM, Vergopoulos A, Erne P. Thiamine supplementation in symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled, cross-over pilot study. Clin Res Cardiol. 2012 Mar;101(3):159-64. [PubMed: 22057652]

²¹DiNicolantonio JJ, Liu J, O’Keefe JH. Thiamine and Cardiovascular Disease: A Literature Review. Prog Cardiovasc Dis. 2018 May-Jun;61(1):27-32. [PubMed: 29360523]

²²Reddy YNV, Melenovsky V, Redfield MM, Nishimura RA, Borlaug BA. High-Output Heart Failure: A 15-Year Experience. J Am Coll Cardiol. 2016 Aug 02;68(5):473-482. [PubMed: 27470455]

²³Chayanupatkul M, Liangpunsakul S. Cirrhotic cardiomyopathy: review of pathophysiology and treatment. Hepatol Int. 2014 Jul;8(3):308-15. [PMC free article: PMC4160726] [PubMed: 25221635]

²⁴Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Delling FN, Djousse L, Elkind MSV, Ferguson JF, Fornage M, Khan SS, Kissela BM, Knutson KL, Kwan TW, Lackland DT, Lewis TT, Lichtman JH, Longenecker CT, Loop MS, Lutsey PL, Martin SS, Matsushita K, Moran AE, Mussolino ME, Perak AM, Rosamond WD, Roth GA, Sampson UKA, Satou GM, Schroeder EB, Shah SH, Shay CM, Spartano NL, Stokes A, Tirschwell DL, VanWagner LB, Tsao CW., American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. Circulation. 2020 Mar 03;141(9):e139-e596. [PubMed: 31992061]

²⁵Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol. 1993 Oct;22(4 Suppl A):6A-13A. [PubMed: 8376698]

²⁶Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, de Ferranti SD, Floyd J, Fornage M, Gillespie C, Isasi CR, Jiménez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Mackey RH, Matsushita K, Mozaffarian D, Mussolino ME, Nasir K, Neumar RW, Palaniappan L, Pandey DK, Thiagarajan RR, Reeves MJ, Ritchey M, Rodriguez CJ, Roth GA, Rosamond WD, Sasson C, Towfighi A, Tsao CW, Turner MB, Virani SS, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P., American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation. 2017 Mar 07;135(10):e146-e603. [PMC free article: PMC5408160] [PubMed: 28122885]

²⁷Yusuf S, Joseph P, Rangarajan S, Islam S, Mente A, Hystad P, Brauer M, Kutty VR, Gupta R, Wielgosz A, AlHabib KF, Dans A, Lopez-Jaramillo P, Avezum A, Lanas F, Oguz A, Kruger IM, Diaz R, Yusoff K, Mony P, Chifamba J, Yeates K, Kelishadi R, Yusufali A, Khatib R, Rahman O, Zatonska K, Iqbal R, Wei L, Bo H, Rosengren A, Kaur M, Mohan V, Lear SA, Teo KK, Leong D, O’Donnell M, McKee M, Dagenais G. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet. 2020 Mar 07;395(10226):795-808. [PMC free article: PMC8006904] [PubMed: 31492503]

²⁸Opie LH, Commerford PJ, Gersh BJ, Pfeffer MA. Controversies in ventricular remodelling. Lancet. 2006 Jan 28;367(9507):356-67. [PubMed: 16443044]

²⁹Kemp CD, Conte JV. The pathophysiology of heart failure. Cardiovasc Pathol. 2012 Sep-Oct;21(5):365-71. [PubMed: 22227365]

³⁰Ait Mou Y, Bollensdorff C, Cazorla O, Magdi Y, de Tombe PP. Exploring cardiac biophysical properties. Glob Cardiol Sci Pract. 2015;2015:10. [PMC free article: PMC4448074] [PubMed: 26779498]

³¹Abassi Z, Khoury EE, Karram T, Aronson D. Edema formation in congestive heart failure and the underlying mechanisms. Front Cardiovasc Med. 2022;9:933215. [PMC free article: PMC9553007] [PubMed: 36237903]

³²Prausmüller S, Arfsten H, Spinka G, Freitag C, Bartko PE, Goliasch G, Strunk G, Pavo N, Hülsmann M. Plasma Neprilysin Displays No Relevant Association With Neurohumoral Activation in Chronic HFrEF. J Am Heart Assoc. 2020 Jun 02;9(11):e015071. [PMC free article: PMC7428996] [PubMed: 32427034]

³³Docherty KF, Vaduganathan M, Solomon SD, McMurray JJV. Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF. JACC Heart Fail. 2020 Oct;8(10):800-810. [PMC free article: PMC8837825] [PubMed: 33004114]

³⁴Obokata M, Reddy YNV, Borlaug BA. Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: Understanding Mechanisms by Using Noninvasive Methods. JACC Cardiovasc Imaging. 2020 Jan;13(1 Pt 2):245-257. [PMC free article: PMC6899218] [PubMed: 31202759]

³⁵Kao DP, Lewsey JD, Anand IS, Massie BM, Zile MR, Carson PE, McKelvie RS, Komajda M, McMurray JJ, Lindenfeld J. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. Eur J Heart Fail. 2015 Sep;17(9):925-35. [PMC free article: PMC4654630] [PubMed: 26250359]

³⁶Harjola VP, Mullens W, Banaszewski M, Bauersachs J, Brunner-La Rocca HP, Chioncel O, Collins SP, Doehner W, Filippatos GS, Flammer AJ, Fuhrmann V, Lainscak M, Lassus J, Legrand M, Masip J, Mueller C, Papp Z, Parissis J, Platz E, Rudiger A, Ruschitzka F, Schäfer A, Seferovic PM, Skouri H, Yilmaz MB, Mebazaa A. Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail. 2017 Jul;19(7):821-836. [PMC free article: PMC5734941] [PubMed: 28560717]

³⁷King M, Kingery J, Casey B. Diagnosis and evaluation of heart failure. Am Fam Physician. 2012 Jun 15;85(12):1161-8. [PubMed: 22962896]

³⁸Ali AS, Rybicki BA, Alam M, Wulbrecht N, Richer-Cornish K, Khaja F, Sabbah HN, Goldstein S. Clinical predictors of heart failure in patients with first acute myocardial infarction. Am Heart J. 1999 Dec;138(6 Pt 1):1133-9. [PubMed: 10577445]

³⁹Klein L, O’Connor CM, Leimberger JD, Gattis-Stough W, Piña IL, Felker GM, Adams KF, Califf RM, Gheorghiade M., OPTIME-CHF Investigators. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation. 2005 May 17;111(19):2454-60. [PubMed: 15867182]

⁴⁰Kelder JC, Cramer MJ, van Wijngaarden J, van Tooren R, Mosterd A, Moons KG, Lammers JW, Cowie MR, Grobbee DE, Hoes AW. The diagnostic value of physical examination and additional testing in primary care patients with suspected heart failure. Circulation. 2011 Dec 20;124(25):2865-73. [PubMed: 22104551]

⁴¹Rørth R, Jhund PS, Yilmaz MB, Kristensen SL, Welsh P, Desai AS, Køber L, Prescott MF, Rouleau JL, Solomon SD, Swedberg K, Zile MR, Packer M, McMurray JJV. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction. Circ Heart Fail. 2020 Feb;13(2):e006541. [PubMed: 32065760]

⁴²Hacker M, Hoyer X, Kupzyk S, La Fougere C, Kois J, Stempfle HU, Tiling R, Hahn K, Störk S. Clinical validation of the gated blood pool SPECT QBS processing software in congestive heart failure patients: correlation with MUGA, first-pass RNV and 2D-echocardiography. Int J Cardiovasc Imaging. 2006 Jun-Aug;22(3-4):407-16. [PubMed: 16328851]

⁴³Jain S, Londono FJ, Segers P, Gillebert TC, De Buyzere M, Chirinos JA. MRI Assessment of Diastolic and Systolic Intraventricular Pressure Gradients in Heart Failure. Curr Heart Fail Rep. 2016 Feb;13(1):37-46. [PubMed: 26780916]

⁴⁴Cahill TJ, Ashrafian H, Watkins H. Genetic cardiomyopathies causing heart failure. Circ Res. 2013 Aug 30;113(6):660-75. [PubMed: 23989711]

⁴⁵Peterson PN, Rumsfeld JS, Liang L, Albert NM, Hernandez AF, Peterson ED, Fonarow GC, Masoudi FA., American Heart Association Get With the Guidelines-Heart Failure Program. A validated risk score for in-hospital mortality in patients with heart failure from the American Heart Association get with the guidelines program. Circ Cardiovasc Qual Outcomes. 2010 Jan;3(1):25-32. [PubMed: 20123668]

⁴⁶Lam CSP, Mulder H, Lopatin Y, Vazquez-Tanus JB, Siu D, Ezekowitz J, Pieske B, O’Connor CM, Roessig L, Patel MJ, Anstrom KJ, Hernandez AF, Armstrong PW., VICTORIA Study Group. Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial. J Am Heart Assoc. 2021 Nov 16;10(22):e021094. [PMC free article: PMC8751950] [PubMed: 34743540]

⁴⁷Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, Lam CSP, Ponikowski P, Voors AA, Jia G, McNulty SE, Patel MJ, Roessig L, Koglin J, O’Connor CM., VICTORIA Study Group. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2020 May 14;382(20):1883-1893. [PubMed: 32222134]

⁴⁸Lucas C, Johnson W, Hamilton MA, Fonarow GC, Woo MA, Flavell CM, Creaser JA, Stevenson LW. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J. 2000 Dec;140(6):840-7. [PubMed: 11099986]

⁴⁹Rider I, Sorensen M, Brady WJ, Gottlieb M, Benson S, Koyfman A, Long B. Disposition of acute decompensated heart failure from the emergency department: An evidence-based review. Am J Emerg Med. 2021 Dec;50:459-465. [PubMed: 34500232]

Disclosure: Ahmad Malik declares no relevant financial relationships with ineligible companies.

Disclosure: Lovely Chhabra declares no relevant financial relationships with ineligible companies.